Moderna (MRNA) Receivables - Other (2017 - 2026)
Moderna (MRNA) posted quarterly Receivables - Other of $40.0 million for Q2 2026, down 14.89% year-over-year from $47.0 million in Q2 2025, and up 2.56% on a QoQ basis from $39.0 million in Q1 2026.
Moderna (MRNA) Receivables - Other (2017 - 2026) Analysis & Trends
Moderna has reported Receivables - Other for 10 years, with the latest figure at $40.0 million in Q2 2026.
- Receivables - Other for Q2 2026 came in at $40.0 million, down 14.89% year-over-year; the trailing twelve-month figure through Jun 2026 was $40.0 million (down 14.89% YoY), and the FY2025 annual result was $42.0 million, down 28.81% from the prior year.
- Receivables - Other grew to $40.0 million in Q2 2026, from $39.0 million in the prior quarter.
- Over five years, Receivables - Other peaked at $69.0 million in Q1 2023 and troughed at $36.0 million in Q1 2022.
- A 5-year average of $52.1 million and a median of $53.5 million in 2022 frame the typical range for Receivables - Other.
- The widest annual swing landed in 2022, when Receivables - Other surged 350.0%; it then fell 28.81% in 2025.
- A 5-year view of Receivables - Other shows it stood at $61.0 million in 2022, then slipped by 3.28% to $59.0 million in 2023, then changed by 0.0% to $59.0 million in 2024, then fell by 28.81% to $42.0 million in 2025, then slipped by 4.76% to $40.0 million in 2026.
- Per Business Quant data, the three most recent Receivables - Other figures were $40.0 million in Q2 2026, $39.0 million in Q1 2026, and $42.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.00 Mn |
| Jun 30, 2026 | 40.00 Mn |
| Mar 31, 2026 | 39.00 Mn |
| Mar 31, 2026 | 39.00 Mn |
| Dec 31, 2025 | 42.00 Mn |
| Dec 31, 2025 | 42.00 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 47.00 Mn |
| Jun 30, 2025 | 47.00 Mn |
| Mar 31, 2025 | 53.00 Mn |
| Mar 31, 2025 | 53.00 Mn |
| Dec 31, 2024 | 59.00 Mn |
| Dec 31, 2024 | 59.00 Mn |
| Sep 30, 2024 | 50.00 Mn |
| Sep 30, 2024 | 50.00 Mn |
| Jun 30, 2024 | 56.00 Mn |
| Jun 30, 2024 | 56.00 Mn |
| Mar 31, 2024 | 62.00 Mn |
| Mar 31, 2024 | 62.00 Mn |